Novavax, Inc. (NVAX)
Pre-market:
| Previous close | 4.7600 |
| Open | 4.9400 |
| Bid | 4.5700 x 300 |
| Ask | 4.6400 x 300 |
| Day's range | 4.4750 - 4.9400 |
| 52-week range | 3.5300 - 10.3000 |
| Volume | |
| Avg. volume | 6,947,895 |
| Market cap | 647.258M |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.4100 |
| Earnings date | 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.40 |
ZacksNovavax (NVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireNovavax to Host Conference Call to Discuss First Quarter 2024 Financial Results and Operational Highlights on May 10, 2024
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024. Details of the event and replay are as follows:
- Reuters
UPDATE 5-Shah Capital urges Novavax shareholders to vote against three directors
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and opposed proposals related to executive compensation, weeks after pushing for a board shakeup at the COVID-19 vaccine maker. Shah Capital, the biotech's third-largest shareholder with a near 7.5% stake, reiterated the company was "undervalued and continues to suffer from poor profitability". The hedge fund had previously said it planned to put forward two of its own candidates for Novavax's board, but was unable to meet the requirements to do so on time.
